Soft-tissue sarcomas. Future perspectives.

F H Sim; J H Edmonson; L E Wold

Home/Archive/PubMed

PubMed · 8472399

Soft-tissue sarcomas. Future perspectives.

F H Sim·J H Edmonson·L E Wold

View original source ↗Export metadata ↓

Abstract

Although the previous outlook for patients with soft-tissue tumors was poor, in recent years advances have been made in earlier recognition and management of soft-tissue sarcomas. Advances include improved clinical pathologic correlation and clinical staging, as well as improved concept of what constitutes adequate surgical management. In addition, recent advances in surgical adjuvant treatment programs promise better results. Moreover, a better understanding of the biology of cancer and the development of sophisticated techniques of molecular biology should lead to more effective treatment.

Explore related subjects

Adjuvants, Immunologic Chemotherapy, Adjuvant Combined Modality Therapy Diagnosis, Differential Forecasting Humans Magnetic Resonance Imaging Neoplasm Recurrence, Local Neoplasm Staging Radiotherapy Sarcoma Sensitivity and Specificity Soft Tissue Neoplasms Survival Rate Tomography, X-Ray Computed Treatment Outcome Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

F H Sim, J H Edmonson, L E Wold. 1993. Soft-tissue sarcomas. Future perspectives.. https://pubmed.ncbi.nlm.nih.gov/8472399/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma.

PURPOSE: We evaluated the role of combining ureteroscopic tumor ablation and new methods of administering topical adjuvant therapy in select patients with transitional cell carcinoma of the upper urinary tract. MATERIALS AND METHODS: Patients with upper tract transitional cell carcinoma and indications for preserving renal function initially underwent ureteroscopic evaluation and tumor ablation. We treated 17 renal units in 13 patients. Three patients with distal ureteral lesions underwent uncomplicated adjuvant bacillus Calmette-Guerin therapy by the combination of Double-J stent placement and bladder instillations in the Trendelenburg position. In the remaining 14 renal units adjuvant topical therapy was administered by low pressure weekly instillations through a transvesical single-J stent whose curl was positioned in an upper calix. Patients were regularly followed with office flexible ureterorenoscopy under local anesthesia and cytology washings once they were confirmed to be tumor-free. RESULTS: Complete ureteroscopic tumor ablation was possible in all patients. Two sessions were needed due to tumor burden in 3 patients. There were intercurrent urinary infectious complications with Candida albicans in the 3 patients treated with bacillus Calmette-Guerin through the single-J stent, including 1 who received only 3 instillations due to persistent unexplained fevers but who remains disease-free at 24 months. In 2 of the 17 renal units multifocal tumor recurred within 12 months, which was treated with nephroureterectomy. At short followup (mean 14.6 months) 15 renal units have been preserved and remain tumor-free. CONCLUSIONS: The new techniques of administering adjuvant topical agents for upper tract transitional cell carcinoma after ureteroscopic tumor ablation in select cases described provide a useful and simple alternative to the percutaneous method preferred in the past. Short-term responses have been favorable but the true value of adjuvant therapy remains uncertain at present. The 2 recurrences within 12 months of treatment were readily detected by outpatient ureterorenoscopy with the patient under local anesthesia using 7.5F flexible endoscopes.

Adjuvants, Immunologic↗

PubMed1997

Adjuvancy effect of different types of silicone gel.

Women with silicone gel-filled breast implants (SBIs) are likely to be at a slightly higher risk of developing an autoimmune-like syndrome. This risk, although small, may be associated with the immunological adjuvancy property of the silicone gel. However, not all silicone gels are chemically formulated exactly the same and their adjuvancy behavior may vary. This study compared, in rats, the adjuvant effect of three different lots of silicone gel using ovalbumin (OVA) as the test antigen. Test bleeds were taken at 21, 48, 62, and 84 days post immunization and the rat sera were analyzed for anti-OVA antibodies by enzyme linked immunosorbent assay (ELISA). A delayed type hypersensitivity (DTH) test was performed on all the treated rats beginning at 14 post-immunization days. The results showed that silicone gel #3 (McGhan lot #S0400488) produced the highest mean anti-OVA antibody titer followed by silicone gel #1 (DC lot #HH019581) and silicone gel #2 (McGhan lot #DP9339). The DTH results showed that rats treated with silicone gel #1 and #3 had a clear positive response, whereas silicone gel #2 caused only a minimal response. These results demonstrate the immunological adjuvancy difference among three types of silicone gel. The chemical composition of each of these silicone gels, that would help explain these results, is yet to be determined.

Adjuvants, Immunologic↗

PubMed1997

Immunopharmacology: immunomodulation and immunotherapy.

Immunopharmacology has changed dramatically over the past 25 years. Although a variety of traditional nonspecific immunosuppressive drug therapies are available for the treatment of autoimmune disease and organ transplantation rejection, with advances in cell biology and monoclonal antibody technology, a highly specific antibody can be engineered to cell surface determinants on immune cells or tumors or to neutralize inflammatory and immune mediators from an immune response. Many of these modalities are still in early phases of study for the treatment of autoimmune disease. In addition to therapies that suppress immune responses, advances in molecular biology have led to new agents and methods to enhance immune responses and correct immune deficits, such as growth factor replacement and cytokine therapies. Finally, gene therapy is a method for the long-term treatment of disorders in which a defective gene leads to disease.

Adjuvants, Immunologic↗